GLORIA
  • 2021 Aug 13
  • The New Normal After Pandemic Focusing on Rapid Screening And Virus Suppression. GLORIA Helping Taiwan's Industry !
Once the new normal after the pandemic makes governments around the world formulate public health strategies fighting the novel coronavirus (COVID-19), improving the efficiency of rapid screening and developing virus suppression products become the core issues of Taiwan's biomedical and technology industries exploring new opportunities under the new normal. GLORIA promoted by the Ministry of Science and Technology (MOST) brings together various rapid screening and virus suppression technologies developed by Taiwan's academia, and there are several results from schools such as NCKU, NSYSU, KMU, CMU and CGU, which have been transferred to Taiwan's companies, further accelerating the exploration for new business opportunities at home and abroad by Taiwan's biomedical and technology industries.

Debut of Global Research & Industry Alliance, GLORIA
Reinforcing Regional and Interschool Industry-Academia Collaboration
The Ministry of Science and Technology started promoting the Global Research & Industry Alliance (GLORIA) in 2017, and has collaborated with industry liaison experts who have industry and venture capital backgrounds to promote academia-industry collaboration and technology transfer with an operational mindset to help academia promote technology, find partnerships and engage in negotiations. It is hoped that the resources from the industry can be incorporated into academia to facilitate collaboration and promote the domestic academic researches and industries to connect with the world.
This year (2021), the former Global Research & Industry Alliance (GLORIA) will integrate relevant industry-academia resources and interschool capacity, and transform itself into " GLORIA 2.0 " to enhance the benefits of regional and interschool industry-academia resources, patents planning and utilization, making industry-academia research and development more focused and effectively consolidating platform resources.

About Ten Rapid Screening Technologies and Services Unveiled
Effectively Enhancing Taiwan's Pandemic Control Capacity
Rapid screening technology is the key to prevent the spread of the novel coronavirus pandemic. The real-time and efficient rapid screening technology can help relevant units find out who may be infected, block the spread of the virus, and enable the society and enterprises to maintain normal functions under the impact of the pandemic. About ten rapid screening technologies and services have been launched on GLORIA, and several of them have completed technology transfer process, creating new opportunities of pandemic control for many Taiwanese companies.
"GLORIA 2.0 SOUTH" corporate member Eternal Materials Co., Ltd. has expanded from the field of synthetic resin to in vitro diagnostics. In addition to in-house R&D, it actively find technical partners through the platform to focus on the development of rapid screening for virus and nucleic acid detection technologies. Leadgene Bio, a startup extended from NCKU, completed its development of rapid screening materials in 2020, and has attracted the attention of businesses around the world, becoming a leader in testing reagent materials in Taiwan.
FJU and Fu Jen Catholic University Hospital of the National Tsing Hua University Scientific Research Industrialization Platform of Five Universities Alliance collaborated on the launch of corporate quick screening services. The services compile and register employees or migrant workers, conduct rapid screening, report the results and positive cases through text messages the following day, and arrange the subsequent PCR tests. The solution is now serving Fubon Group, Yuanta Financial Holdings, Advantech, Kindom Construction and other businesses.
The team of Professor Wen-Liang Chen from NYCU of the New Industries Alliance developed a quantitative electronic chip rapid screening platform which can complete the rapid screening of novel coronavirus under 5 minutes, and then determine the current phase of infection based on the data of antibodies, antigens, and nucleic acids. The platform has acquired TFDA, CE and Thailand FDA certifications.
NSYSU of Southern Taiwan Gloria has introduced an ultra-sensitive COVID-19 lgM antibody rapid screening technology. Only a drop of blood is needed to quickly screen out early infections without obvious symptoms under 15 minutes, so that quarantine and treatment can given as soon as possible. KMU has developed a fully automatic rapid screening reagent for novel coronavirus. Adding samples from patients to the reagents, and the test results can be analyzed through fully automated instruments, which can quickly perform screening in large quantities at low cost. KMU at the same time has launched fixed-temperature chemical nucleic acid detection technology. It is the first fixed-temperature nucleic acid detection medical material approved by the Ministry of Health and Welfare for project manufacturing in Taiwan. The detection process does not require temperature control, and the detection time is only a quarter of the traditional method, while offering high accuracy.
On the Global Industry Platform (GIP) of NTU System (T4 GIP), NTU collaborates with businesses to provide biotechnology, big data and AI technologies focusing on the novel coronavirus activity, advanced vaccines, development of rapid screening reagent and field validation. CGU's Research Center for Emerging Viral Infections has developed a novel coronavirus neutralizing antibody titer assay kit. After the binding of neutralizing antibody and specific protein for 1.5 hours, the kit can quickly and accurately identify whether there are virus-inhibiting neutralizing antibodies inside the body. The technology has been transferred to Formosa Biomedical Technology Corporation.
At the Taiwan Gloria Center, Taipei Medical University Hospital has collaborated with the Industrial Technology Research Institute, Radica Health, Tranwo Technology, Microsoft Taiwan, Acer ACEB and other industry-academia collaboration teams to launch the "Contactless pandemic control technology platform". It can automatically measure, compile, and interpret patients' data, and issue immediate warning messages if there is an abnormality. The platform offers real-time videoconferencing interactions to reduce contacts between people, further protecting the front-line medical personnel.

GLORIA Providing Key Viral Suppression Technologies and Function Validation Services
Governments around the world believe that coexistence with the novel coronavirus may be the next necessary direction to be taken, which also simultaneously drives the demand for virus suppression products from companies, government agencies and the general public. As long as the virus can be effectively prevented from spreading through daily necessities, people can reduce their risks of infection caused by viruses hidden in the environment. As a results, the Platform provides key viral suppression technologies and function validation services developed by academia, accelerating companies' progress in developing anti-virus products.
The team of Professor Dean-Mo Liu from NYCU of the New Industries Alliance has developed the "Biogel antivirus nano coating technology" which can be applied to masks for viral suppression and killing of viruses. NYCU also has established one of the only two research centers for epidemic prevention in Taiwan. It consolidates the efforts of Taipei Veterans General Hospital, National Yang Ming University Hospital and Taoyuan Hospital of the Ministry of Health and Welfare and collaborates with domestic companies such as Medigen, Acer, Formosa Laboratories and SyneuRx on reagents, drugs, vaccines, regulations and smart medical care. It also provides research and development services for clinical and pathological, medicine and prevention, testing and quarantine, public health and epidemics, psychology, social, and international collaboration fields.
NSYSU of Southern Taiwan GLORIA has launched a nano-shield pandemic control spray. The spray can be suspended in the air for up to two hours and bind with the novel coronavirus to cause it to settle. It can bind with 40% to 60% of novel coronavirus in the air within 30 minutes, further reducing the risk of virus transmission. The Pseudovirus-SARS-CoV-2 cell infection test confirmed that the efficiency of inhibiting the virus infecting cells can reach 67.8%. It has been confirmed that it does not cause inhalation toxicity, skin irritation, and eye irritation.
On the Taoyuan-Taichung Scientific Research & Industrialization Platform Project, Principal and fellow Mien-Chie Hung of China Medical University used a newly constructed molecular cell rapid screening platform to find inhibitors that can fight Alpha variant (UK variant) and Beta variant (South Africa variant) through the Chinese Pharmacopoeia and natural products. The Research and Development Center for Membrane Technology of Chung Yuan Christian University has collaborated with a biotechnology company to develop a nanofiber collector that can efficiently capture viruses to improve sampling efficiency and detection sensitivity. Professor Yi-Ning Chen of the Department of Bioscience Technology at Chung Yuan Christian University has helped a technology company develop performance validation of COVID-19 viral suppression materials.
On GLORIA 2.0 SOUTH, Meet Tec, a startup extended from NCKU, used a single coating technology to enhance the electrostatic filtration performance to inhibit the proliferation of bacteria and viruses and prevent blood penetration, which can be applied to products related to pandemic control.
On the Global Industry Platform (GIP) of NTU System (T4 GIP), CGU's Research Center for Emerging Viral Infections has helped Formosa Biomedical Technology Corporation test antibacterial spray. The experimental results confirmed that its performance inhibiting the novel coronavirus exceeded 99.99%.

GLORIA Quickly Providing R&D Technologies Developed by Academia
The Platform promoted by the Ministry of Science and Technology brings together various technologies developed by Taiwan's academia.
本網站使用您的Cookie於優化網站及您的瀏覽經驗。繼續瀏覽網站即表示您同意本公司隱私權政策,您可至隱私權政策了解詳細資訊。